PMID- 18612103
OWN - NLM
STAT- MEDLINE
DCOM- 20081112
LR  - 20220330
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 112
IP  - 9
DP  - 2008 Nov 1
TI  - A prospective PETHEMA study of tandem autologous transplantation versus autograft 
      followed by reduced-intensity conditioning allogeneic transplantation in newly 
      diagnosed multiple myeloma.
PG  - 3591-3
LID - 10.1182/blood-2008-02-141598 [doi]
AB  - One hundred ten patients with multiple myeloma (MM) failing to achieve at least 
      near-complete remission (nCR) after a first autologous stem cell transplantation 
      (ASCT) were scheduled to receive a second ASCT (85 patients) or a 
      reduced-intensity-conditioning allograft (allo-RIC; 25 patients), depending on 
      the human leukocyte antigen (HLA)-identical sibling donor availability. There was 
      a higher increase in complete remission (CR) rate (40% vs 11%, P = .001) and a 
      trend toward a longer progression-free survival (PFS; median, 31 months vs not 
      reached, P = .08) in favor of allo-RIC. In contrast, it was associated with a 
      trend toward a higher transplantation-related mortality (16% vs 5%, P = .07), a 
      66% chance of chronic graft-versus-host disease and no statistical difference in 
      event-free survival and overall survival. Although the PFS plateau observed with 
      allo-RIC is very encouraging, this procedure is associated with high morbidity 
      and mortality, and therefore it should still be considered investigational and 
      restricted to well-designed prospective clinical trials. This trial is registered 
      at ClinicalTrials.gov ID number NCT00560053.
FAU - Rosinol, Laura
AU  - Rosinol L
AD  - Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer 
      (IDIBAPS), Barcelona, Spain.
FAU - Perez-Simon, Jose Antonio
AU  - Perez-Simon JA
FAU - Sureda, Anna
AU  - Sureda A
FAU - de la Rubia, Javier
AU  - de la Rubia J
FAU - de Arriba, Felipe
AU  - de Arriba F
FAU - Lahuerta, Juan Jose
AU  - Lahuerta JJ
FAU - Gonzalez, Jose David
AU  - Gonzalez JD
FAU - Diaz-Mediavilla, Joaquin
AU  - Diaz-Mediavilla J
FAU - Hernandez, Belen
AU  - Hernandez B
FAU - Garcia-Frade, Javier
AU  - Garcia-Frade J
FAU - Carrera, Dolores
AU  - Carrera D
FAU - Leon, Angel
AU  - Leon A
FAU - Hernandez, Miguel
AU  - Hernandez M
FAU - Abellan, Pascual Fernandez
AU  - Abellan PF
FAU - Bergua, Juan Miguel
AU  - Bergua JM
FAU - San Miguel, Jesus
AU  - San Miguel J
FAU - Blade, Joan
AU  - Blade J
CN  - Programa para el Estudio y la Terapeutica de las Hemopatias Malignas y Grupo 
      Espanol de Mieloma (PETHEMA/GEM)
LA  - eng
SI  - ClinicalTrials.gov/NCT00560053
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080708
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
CIN - Blood. 2008 Nov 1;112(9):3532. PMID: 18948579
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Disease-Free Survival
MH  - Graft vs Host Disease/etiology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Multiple Myeloma/*therapy
MH  - Prospective Studies
MH  - *Stem Cell Transplantation/adverse effects/mortality
MH  - Transplantation Conditioning
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
EDAT- 2008/07/10 09:00
MHDA- 2008/11/13 09:00
CRDT- 2008/07/10 09:00
PHST- 2008/07/10 09:00 [pubmed]
PHST- 2008/11/13 09:00 [medline]
PHST- 2008/07/10 09:00 [entrez]
AID - S0006-4971(20)51918-6 [pii]
AID - 10.1182/blood-2008-02-141598 [doi]
PST - ppublish
SO  - Blood. 2008 Nov 1;112(9):3591-3. doi: 10.1182/blood-2008-02-141598. Epub 2008 Jul 
      8.